- Home
- WGRX vs FBRX Comparison
WGRX vs FBRX Comparison
Compare WGRX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- FBRX
- Stock Information
- Founded
- WGRX 2022
- FBRX N/A
- Country
- WGRX United States
- FBRX United States
- Employees
- WGRX N/A
- FBRX N/A
- Industry
- WGRX Other Pharmaceuticals
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- FBRX Health Care
- Exchange
- WGRX Nasdaq
- FBRX Nasdaq
- Market Cap
- WGRX 66.1M
- FBRX 69.7M
- IPO Year
- WGRX 2025
- FBRX N/A
- Fundamental
- Price
- WGRX $0.86
- FBRX $12.48
- Analyst Decision
- WGRX
- FBRX Strong Buy
- Analyst Count
- WGRX 0
- FBRX 2
- Target Price
- WGRX N/A
- FBRX $61.00
- AVG Volume (30 Days)
- WGRX 230.7K
- FBRX 178.2K
- Earning Date
- WGRX 08-11-2025
- FBRX 08-13-2025
- Dividend Yield
- WGRX N/A
- FBRX N/A
- EPS Growth
- WGRX N/A
- FBRX N/A
- EPS
- WGRX N/A
- FBRX N/A
- Revenue
- WGRX $28,992,274.00
- FBRX N/A
- Revenue This Year
- WGRX N/A
- FBRX N/A
- Revenue Next Year
- WGRX N/A
- FBRX N/A
- P/E Ratio
- WGRX N/A
- FBRX N/A
- Revenue Growth
- WGRX N/A
- FBRX N/A
- 52 Week Low
- WGRX $0.82
- FBRX $4.11
- 52 Week High
- WGRX $7.04
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- FBRX 53.09
- Support Level
- WGRX N/A
- FBRX $10.15
- Resistance Level
- WGRX N/A
- FBRX $14.49
- Average True Range (ATR)
- WGRX 0.00
- FBRX 1.96
- MACD
- WGRX 0.00
- FBRX -0.19
- Stochastic Oscillator
- WGRX 0.00
- FBRX 24.58
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).